This disclosure relates to pharmaceutical compositions and formulations useful for inhibiting the progression of glycine encephalopathy. The pharmaceutical compositions and formulations may include glyceryl tribenzoate. The pharmaceutical compositions and formulations may include glyceryl dibenzoate. The pharmaceutical compositions and formulations may be orally administered to the patient.